| CAS |
78919-13-8 |
| Chinese Name |
伊洛前列素 |
| English Name |
Iloprost |
| Synonyms |
Ciloprost;ZK 36374 |
| Molecular Formula |
C22H32O4 |
| Molecular Weight |
360.49 |
| Solubility |
Soluble in DMSO |
| Purity |
HPLC≥98% |
| Appearance |
Solid |
| Storage |
Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL |
MFCD00867145 |
| SMILES |
O=C(O)CCC/C=C1C[C@@]2([H])C[C@@H](O)[C@H](/C=C/[C@@H](O)C(C)CC#CC)[C@@]2([H])C\1 |
| InChIKey |
HIFJCPQKFCZDDL-ACWOEMLNSA-N |
| InChI |
InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1 |
| PubChem CID |
5311181 |
| Target Point |
Prostaglandin Receptor |
| Passage |
Endocrinology & Hormones;GPCR & G Protein |
| Background |
It is a stable prostacyclin analog. |
| Biological Activity |
Iloprost (ZK 36374; Ciloprost) is a prostacyclin (PGI2) analogue， involves in embryo development and inflammation improvement， and inhibits tumor metastasis. Iloprost can be used for peripheral vascular research[1][2][3][4]. |
| IC50 |
IP |
| In Vitro |
Prostacyclin (PGI2) is synthesised in oviductal fluid and enhance the embryo development[1].Iloprost is an PGI2 analog， and affects maturation and developmental competence of bovine oocytes[1].Iloprost (0.5 μM; 22-24 h) increases blastocyst rates of bovine embryos as well as proportion of expanded blastocysts[1].Iloprost (0.5 μM; 22-24 h) assists maturation rates and cumulus cell expansion of bovine oocytes， and increases the mRNA expression of genes related to cumulus expansion[1].Iloprost (0.5 μM; 22-24 h) reduces the occurrence of apoptosis in COCs and promotes an anti-apoptotic balance in the transcription of genes involved in apoptosis (BAX and BCL2) [1]. |
| In Vivo |
Iloprost (0.3 mg/kg/min; via s.c. mini pumps; 33 d) has a significant anti-metastatic activity in a spontaneously metastasizing tumor model in rat[2].Iloprost (0.2 mg/kg/d; i.p.; 10 d) attenuates hyperoxia effects and reduces inflammation in the newborn mouse lung， with Cyclooxygenase-2 (COX-2/PTGS2) mediates hyperoxia-induced impairment[3].Iloprost (0.2 mg/kg; i.v. or i.p.) exhibits short half-life， and is often administered by means of frequent (every 2-4h) inhalation in treatment[4]. |
| Data Literature Source |
[1]. Kowalczyk-Zieba I，et al. Iloprost affects in vitro maturation and developmental competence of bovine oocytes. Theriogenology. 2020 Nov;157:286-296.
[2]. Hildebrand M. Pharmacokinetics of iloprost and cicaprost in mice. Prostaglandins. 1992 Nov;44(5):431-42.
[3]. Olave N，et al. Iloprost attenuates hyperoxia-mediated impairment of lung development in newborn mice. Am J Physiol Lung Cell Mol Physiol. 2018 Oct 1;315(4):L535-L544.
[4]. Schneider MR，et al. Effects of prostacyclin analogues in in vivo tumor models. Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:901-8. |
| Unit |
Bottle |
| Specification |
1mg 5mg |
English
中文
Manual Download
